Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2024-12-23 00:00:00 ET · period of report 2024-12-19 · accession 0001127602-24-029948 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-23 | 2024-12-19 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | A - Grant | $0.00 | +362.1K | 1.46M | +33% | $0 |
| DMI | 2024-12-23 | 2024-12-20 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | G - Gift | $0.00 | +20.0K | 30.0K | +200% | $0 |
| D | 2024-12-23 | 2024-12-19 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | F - Tax | $7.39 | -14.0K | 1.45M | -1.0% | -$103.5K |
| D | 2024-12-23 | 2024-12-20 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | G - Gift | $0.00 | -20.0K | 1.43M | -1% | $0 |
| D | 2024-12-23 | 2024-12-19 | BCRX | Stonehouse Jon P | Pres, CEO, Dir | A - Grant | $0.00 | +750.2K | 750.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-19 | A | A | 362,100 | $0.00 | 1,463,119 | D By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust | — | — | (F1) Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| 2 | Common | Common Stock | 2024-12-20 | G | A | 10,000 | $0.00 | 30,000 | I | — | — | |
| 3 | Common | Common Stock | 2024-12-19 | F | D | 14,010 | $7.39 | 1,449,109 | D By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust | — | — | (F2) Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person. |
| 4 | Common | Common Stock | 2024-12-20 | G | A | 10,000 | $0.00 | 30,000 | I | — | — | |
| 5 | Common | Common Stock | 2024-12-20 | G | D | 20,000 | $0.00 | 1,429,109 | D | — | — | |
| 6 | Derivative | Emp. Stock Option (Right to Buy) | 2024-12-19 | A | A | 750,250 | $0.00 | 750,250 | D | $7.39 · 2025-12-19 to 2034-12-19 | 750,250 Common Stock | (F4) Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |